Advanced search×

Irritable bowel syndrome, depression, and Th-1 autoimmune diseases.

Fuad F Lechin and Bertha B van der Dijs

Dig Dis Sci 52(1):103-4 (2007) PMID 17160472

DOI: 10.1007/s10620-006-9505-6
Version: za2963e q8za6 q8zbf q8zcc q8zd9 q8zec q8zf6 q8zg4
Buy PDF

Similar articles you may find interesting…

  1. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....
    Buy PDF
  2. Immune Activation in Irritable Bowel Syndrome: Can Neuroimmune Interactions Explain Symptoms?
    Patrick A Hughes, Heddy Zola, and Doreen Krumbiegel

    Am J Gastroenterol (2013) PMID 23649183

    Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal (GI) tract characterized by pain or discomfort from the lower abdominal region, which is associated with altered bowel habit. Despite its prevalence, there is currently a lack of effective treatment optio...
    Buy PDF
  3. Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins.
    Indrajit Das, Chin Wen Png, and Michael A McGuckin

    J Exp Med (2013) PMID 23650437

    Endoplasmic reticulum (ER) stress in intestinal secretory cells has been linked with colitis in mice and inflammatory bowel disease (IBD). Endogenous intestinal glucocorticoids are important for homeostasis and glucocorticoid drugs are efficacious in IBD. In Winnie mice with intestin...
    Buy PDF